KPCIRC sign-off process
The treating oncologistowns everything.
“The treating oncologist makes every treatment decision.”
Structured report
Try it · Twin sign-off sequence
Follow a report to the oncologist's signature.
Step through the Twin sign-off sequence. At every step, clinical authority stays with the treating oncologist. AVATAR's documented sequence differs and is shown separately below.
Step 1 of 6 · Treating team
Pathway and data
The treating oncologist selects the testing pathway; clinical, molecular and imaging data are integrated.
Sequence.
Ownership principles
Four commitments to the treating oncologist
- 01
You decide
Clinical authority stays with you.
Every treatment decision is made by the treating oncologist. OnKommon outputs are information for that decision, never a substitute for it.
- 02
You review and sign
Every report reviewed and signed by you.
No Twin report is final until the treating oncologist has reviewed and signed it. For AVATAR, the treating oncologist finalises and signs the integrated report after Molecular Tumour Board review.
- 03
You control access
Access follows your approved workflow.
The Clinical Twin belongs to the treating oncologist and their patient. Who can see and contribute to it follows the oncologist's approved workflow.
- 04
The Twin evolves with you
New evidence can prompt reassessment.
When new findings or evidence arrive, the oncologist decides whether reassessment is warranted and what, if anything, changes.
The sign-off sequence
How each offering is reviewed and signed
OnKommon Twin
In the Twin workflow“Every report reviewed and signed by the treating oncologist, then taken to KPCIRC's internal Molecular Tumour Board (MTB).”
- 1
Treating team
Pathway and data
The treating oncologist selects the testing pathway; clinical, molecular and imaging data are integrated.
- 2
OnKommon Twin
21-layer analysis
AI-assisted analysis across the applicable layers produces structured findings for clinician review.
- 3
OnKommon Twin
Structured report
Executive summary, molecular findings, treatment options to evaluate, trial matches and longitudinal view.
- 4
Treating oncologist
Review and signature
Every report is reviewed and signed by the treating oncologist.
- 5
KPCIRC
Molecular Tumour Board
The signed report is then taken to KPCIRC's internal Molecular Tumour Board (MTB).
- 6
Treating oncologist
Decision and continuity
Clinical authority stays with the oncologist. New evidence can prompt reassessment during the six-month journey.
OnKommon AVATAR
AVATAR governance“Every integrated report is reviewed by KPCIRC's Molecular Tumour Board (MTB), then finalised and signed by the treating oncologist, who keeps clinical ownership of every treatment decision.”
- 1
OnKommon Interpreter
Computational evidence
Computational interpretation of tumour alterations and the evidence linked to treatment response.
- 2
AVATAR Discovery Process
Experimental evidence
Mutation-informed biological modelling and drug screening on the fruit-fly platform.
- 3
OnKommon AVATAR
Integrated report
Molecular findings, screening observations, limitations and considerations for assessment.
- 4
KPCIRC
Molecular Tumour Board review
Reviews the findings, their interpretation, clinical context and therapeutic implications.
- 5
Treating oncologist
Finalisation and signature
Finalises and signs the report, and retains ultimate clinical ownership and responsibility for treatment decisions.
Constant across both
What never changes
- The treating oncologist signs the report.
- The treating oncologist makes every treatment decision.
- KPCIRC's Molecular Tumour Board provides multidisciplinary review.
- Clinical interpretation is provided by qualified clinicians.
- Software outputs are information for review — never a decision.
What OnKommon software never does
- Diagnoses a patient
- Prescribes or recommends a treatment autonomously
- Signs a report
- Makes a treatment decision
- Communicates a decision to the patient
Responsibility boundaries
Who is responsible for what
- 01
Software-generated findings
OnKommon analytical layers
Structured, AI-assisted analytical outputs from the available data.
Not a diagnosis, recommendation or decision.
- 02
Automated annotation and computational interpretation
OnKommon Twin · OnKommon Interpreter
Variants annotated and connected to evidence; computational observations labelled as such.
Does not establish clinical significance for the individual patient on its own.
- 03
Expert scientific review
Qualified clinicians and scientists
Clinical interpretation is provided by qualified clinicians.
- 04
Genetic counselling, where applicable
Genetic counselling services
Possible inherited findings need counselling and confirmatory testing.
- 05
Treating clinician assessment
Treating oncologist
Reviews and signs every Twin report; finalises and signs AVATAR integrated reports.
- 06
Multidisciplinary / molecular tumour board
KPCIRC Molecular Tumour Board
Reviews findings, interpretation, clinical context and therapeutic implications.
- 07
Final clinical decision and communication to the patient
Treating oncologist, with the patient
The treating oncologist makes every treatment decision and communicates it to the patient.
KPCIRC
Kwatra Precision Cancer Institute & Research Centre
KPCIRC is the affiliated clinical partner. It convenes the Molecular Tumour Board that reviews OnKommon findings, their interpretation, clinical context and therapeutic implications. KPCIRC is distinct from the OnKommon product brand.
Questions about clinical governance?
Talk to the team about the sign-off sequence, the Molecular Tumour Board and how access is controlled.